Biogen Idec Ma Inc.

Nsgene A/s

Institut National De La Sante Et De La Recherche Medicale

Biogen Ma Inc.

Gloriana Therapeutics Sarl

Gloriana Therapeutics, Inc.

Arizona Board of Regents on Behalf of the University of Arizona

Inserm

Anthony Rossomando

R Blake Pepinsky

Dinah Wen-Yee Sah

Teit E Johansen

Dinah W Y Sah

Laura Silvian

Paula Ann Boriack-Sjodin

Radia Tamarat

Jean-Sebastien Silvestre

BangJian Gong

Stephan S Miller

Ping Jin

Frank Porreca

Jean-Sébastien Silvestre

Blake R Pepinsky

Dinah W Sah

Dinah Wen Yee Sah

Banjian Gong

Disclosed are methods of improving impaired proprioception, treating brachial plexus injuries, regenerating large and small nerve fibers, treating dorsal root nerve injuries, and improving sensory neural responses in a subject by administration of a neublastin polypeptide.

Treatments for neurological disorders

Antibodies and antigen binding fragments that bind to neublastin polypeptides are disclosed. Also disclosed are methods of using the antibodies and antigen binding fragments in assays for detecting the presence or amount of endogenous and/or exogenous neublastin in a sample and in methods of antagonizing neublastin bioactivity.

Anti-neublastin antibodies and uses thereof

Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject.

Compositions and methods for increasing vascularization

Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.

Refolding transforming growth factor beta family proteins

The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin.

Polymer-conjugated glycosylated neublastin

Methods for increasing vascularization

Neublastin variants

The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.

Neurotrophic factors and methods of use thereof

Polymer conjugated glycosylated neublastin

A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.

Polymer conjugates of mutated neublastin

Methods of activating RET receptor tyrosine kinase using neurotrophic factors

Methods of treating pain using neurotrophic factors

Neurotrophic factors

Growing community of inventors

South Grafton, MA, United States of America

Anthony Rossomando